Lastest from Businesswire

Subscribe to Lastest from Businesswire feed Lastest from Businesswire
Business Wire - The global leader in news distribution
Updated: 2 hours 27 min ago

Schwab Asset Management Reduces Fees on Four Equity Index ETFs

Thu, 06/11/2026 - 08:50
WESTLAKE, Texas--(BUSINESS WIRE)--Schwab Asset Management®, the asset management arm of The Charles Schwab Corporation and the fifth-largest provider1 of ETFs, today announced the reduction of operating expense ratios for four equity index ETFs: the Schwab U.S. Mid-Cap ETF (SCHM), Schwab U.S. Small-Cap ETF (SCHA), Schwab International Small-Cap Equity ETF (SCHC), and Schwab Emerging Markets Equity ETF (SCHE). The fee reductions are effective June 11, 2026. Out of Schwab Asset Management’s 24 ma

WGS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Thu, 06/11/2026 - 08:50
SAN DIEGO--(BUSINESS WIRE)---- $WGS #GeneDx--The case alleges GeneDx and certain of its top executives made false and/or misleading statements to investors.

Modiv Industrial Declares Quarterly Dividends for Preferred Shareholders and Monthly Distributions for Common Shareholders

Thu, 06/11/2026 - 08:50
DENVER--(BUSINESS WIRE)--Modiv Industrial, Inc. (“Modiv Industrial,” “Modiv” or the “Company”) (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate properties, announced the declaration of a regular quarterly cash dividend of $0.4609375 per share on the Company’s 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value per share (the “Series A Preferred Stock”), for the second quarter of 2026 and the declaration of regul

CoreWeave Announces Intention to Offer $3.5 Billion of Senior Notes

Thu, 06/11/2026 - 05:49
LIVINGSTON, N.J.--(BUSINESS WIRE)--CoreWeave, Inc. (Nasdaq: CRWV) (“CoreWeave”) announced today that it intends, subject to market and other customary conditions, to offer $3.5 billion (or euro equivalents) in aggregate principal amount of dollar-denominated and euro-denominated senior notes due 2032 (collectively, the “Notes”) in a private offering. The Notes will be guaranteed on a senior unsecured basis by certain wholly-owned subsidiaries of CoreWeave. CoreWeave intends to use the proceeds

Motive Partners Invests in Mobius to Build the Future of Pension and Wealth Investment Infrastructure

Thu, 06/11/2026 - 05:49
NEW YORK & LONDON--(BUSINESS WIRE)--Motive Partners (“Motive”), a specialist private investment firm focused on financial technology, today announced a strategic investment in Mobius, a leading UK based pension investment platform, to accelerate the development of next-generation investment infrastructure across pensions and wealth. Motive purchased Mobius from Phoenix Equity Partners, and the transaction is expected to close later this year, subject to customary closing conditions. Mobius is a

ACI Worldwide Powers Next-Generation PSP Expansion in Africa with Kwik Payments Go-Live

Thu, 06/11/2026 - 02:49
OMAHA, Neb. & JOHANNESBURG--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced that Kwik Payments, a South Africa-based payments service provider (PSP), has successfully gone live on the ACI Payments Orchestration Platform, to power the next phase of digital commerce growth across South Africa and the wider African market. The partnership represents a pivotal milestone in ACI’s expansion across Africa, reinforcing its growing foot

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit

Wed, 06/10/2026 - 23:49
SAN DIEGO--(BUSINESS WIRE)---- $ADMA #ADMABiologicsInc--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.For more information, submit

Pages